Abstract 16926: The Effects of a Mitochondrial Targeted Ubiquinone (MitoQ) on Vascular Function in Chronic Kidney Disease

• DOI: 10.1161/circ.142.suppl_3.16926
• Publication Date: 2021-05-10T17:33:21Z
• Authors: Danielle L Kirkman; Ninette Shenouda; Joseph M Stock; Bryce J Muth; Nicholas Chouramanis; Raymond R Townsend; David G Edwards
• Keywords: Brachial artery

Introduction: Aberrant vascular function contributes to the substantially high cardiovascular burden of chronic kidney disease (CKD). Mitochondrial derived oxidative stress is a potential therapeutic target ameliorate CKD related dysfunction. Hypothesis: We hypothesized that mitochondrial targeted antioxidant (MitoQ) would improve in Stage 3-5 patients without overt disease. Methods: In this controlled, double-blind trial, 18 (Mean±SEM: Age, 62±3 years; eGFR, 45±3 ml•min•1.73 2 ) were randomized receive an oral dose MitoQ (20mg/day; MTQ) or Placebo (PLB) for 4 weeks. Outcome measures assessed at week 0 and 4. Aortic pressure waves synthesized from brachial artery waveforms acquired by oscillometry use generalized transfer function. The central waveform was separated into forward reflected using triangular flow waveform. Conduit via mediated dilation (FMD). Results: well tolerated patient compliance (MTQ, 99.6±0.4%; PLB, 97.8±2.2%). Independent peripheral (Baseline vs. Follow Up: MTQ, 140±6 137±6 mmHg; 136±4 134±6 interaction p=0.7) 128±5 123±6 124±3 123±5 p=0.8) systolic blood pressures, maintained wave amplitudes 31±3 29±1 29±3 36±3 p=0.05) tended reduce 18±2 16±1 19±2 21±2 p=0.04). administration favored improvements FMD 2.4±0.3 4.0±0.9%; 4.2±1.0 2.5±1.0%; Conclusions: These results suggest targeting reactive oxygen species holds promise as strategy Whether arterial hemodynamics are result augmented cardiac reduction resistance warrants future investigation larger studies.